BOTHELL, Wash. and VANCOUVER, British Columbia, March. 6, 2018 – – Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced that the World Conference on Tobacco or Health (WCTOH) will be holding a symposium on cytisine research at this year’s annual conference, March 7-9th in Cape Town, South Africa.

The cytisine symposium titled “Is a Globally Affordable Medication to Treat Tobacco Dependence Achievable? The Case of Cytisine.” will be held on Friday, March 9th at 7:45am. Nancy Rigotti, MD, Professor of Medicine, Harvard Medical School and Director, Tobacco Research and Treatment Center, at Massachusetts General Hospital will chair the symposium. Further to Achieve’s collaboration with the National Institutes of Health (NIH) to advance cytisine research, Dr. David Shurtleff, PhD, Acting Director at the NIH, National Center for Complementary and Integrative Health, will be presenting “An Overview of the Safety Assessment for Regulatory Approval of Cytisine in the U.S.”

Dr. Anthony Clarke, PhD, Chief Scientific Officer of Achieve commented, “Significant clinical development progress has been made recently with completion of a Phase I/II trial. Achieve is focused on commencing Phase 3 clinical trials in mid-2018 and appreciates the contributions from the scientific community in aiding the regulatory approval process for cytisine as a cost-effective smoking cessation treatment.”

Two Phase 3 clinical trials of cytisine have been successfully completed in over 2,000 patients. The TASC Phase 3 trial was a 740 patient, double-blind placebo controlled trial conducted by University College London. The CASCAID trial was a 1,310 patient, single-blind trial c